New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was 0.00% in FY25, against a low of −421.8% in FY22. ROE, at 51.9%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−73.5%−84.5%−67.2%−66.4%3.9%−37.1%−44.2%−109.8%172.7%51.9%
ROIC0.0%0.0%0.0%−199.1%4.7%−89.2%−421.8%0.0%0.0%0.0%

Debt

Net debt is 1.15× a year’s EBITDA.

Net debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net debt / EBITDA1.0×1.6×2.1×1.4×−27.0×1.9×1.7×0.8×0.0×1.1×

Cash cycle, in days

Customers pay in 230 days, inventory is held 530 days and suppliers are paid in 1287. Suppliers fund 527 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
FY21FY22FY24
Cash cycle−696−324−527
Days to pay suppliers13214821287
Days to be paid1839230

Per share, from FY16

Since FY16, per share: revenue has grown 49.1% a year.

RevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24
Revenue1.0×9.3×119.1×147.9×904.1×144.1×247.5×122.8×24.4×
Book value1.0×1.5×2.0×2.4×2.8×2.4×1.6×0.6×−0.5×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
2 4 4 2 5 2 3 2 3 —
P/E ratio
0.00 0.00 0.00 0.00 168.02 0.00 0.00 0.00 0.00 —
Altman Z-Score
5.96 18.28 2.27 5.64 18.74 15.90 9.99 (9.42) (5.15) —
P/S ratio
3,094.60 401.66 32.43 34.55 5.31 4.57 14.03 1.95 6.62 —
Altman Z″-Score (non-manufacturers)
(5.24) 3.24 (0.91) (1.13) 11.49 7.60 (1.01) (18.63) (10.69) —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
(20.18) (35.09) (19.14) (22.05) 8.74 (495.98) (24.99) (2.36) (9.78) —
Beneish M-Score
67.91 5.26 12.86 (1.55) 1.40 (2.84) (1.22) (3.39) (3.66) —
P/B ratio
5.25 4.61 3.49 3.68 2.88 2.71 3.70 0.72 0.00 —
EV/Sales
2,408.83 308.81 21.18 26.93 4.00 3.35 10.55 (2.87) 6.43 —
EV/EBITDA
0.00 0.00 0.00 0.00 82.36 0.00 0.00 0.50 0.00 —
EV/FCF
(4.31) (5.61) (13.62) (4.90) (92.50) (7.53) (5.61) 0.64 (2.14) —
Current Ratio
5.33 11.18 4.16 3.86 10.55 9.84 7.20 4.54 3.06 2.86
Net Debt/EBITDA
1.03 1.55 2.05 1.35 (27.04) 1.91 1.70 0.85 0.05 1.15
Debt/Equity
0.00 0.00 0.00 0.02 0.01 0.01 0.00 0.00 (0.33) 0.00
ROE
(73.54%) (84.54%) (67.16%) (66.41%) 3.86% (37.12%) (44.25%) (109.80%) 172.69% 51.90%
ROA
(65.57%) (72.28%) (51.43%) (50.20%) 3.34% (34.13%) (39.82%) (76.94%) (36.51%) (54.15%)
ROIC
0.00% 0.00% 0.00% (199.09%) 4.69% (89.22%) (421.75%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(111.17%) (66.26%) (57.57%) (86.16%) 4.74% (56.58%) (58.59%) (126.23%) (137.35%) (88.64%)
Average Days of Receivables
3,985.29 342.16 43.09 32.80 5.58 18.26 38.82 69.93 229.88 —
Earnings Yield
(21.53%) (14.88%) (15.85%) (15.46%) 0.60% (14.21%) (14.53%) (288.35%) (62.17%) —
Free Cash Flow Yield
(18.07%) (13.70%) (4.80%) (15.90%) (0.81%) (9.73%) (13.41%) (230.65%) (45.36%) —
Free Cash Flow per Share
(63.50) (63.31) (22.45) (92.21) (4.43) (42.65) (52.86) (62.81) (7.52) (3.17)
Book value per Share
66.97 100.17 134.10 157.60 189.15 161.57 106.55 37.96 (35.40) 2.82
Free Cash Flow
(48.10) (54.84) (22.37) (109.24) (5.84) (60.06) (78.77) (94.45) (19.35) (23.50)
EV/EBIT
0.00 0.00 0.00 0.00 100.24 0.00 0.00 0.50 0.00 —
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 17, 2026